Ascletis announces phase IIb trial results of subcutaneous PD-L1 antibody envafolimab in patients with chronic hepatitis B (CHB) at an oral parallel session of ILC 2022

Ascletis Pharma Inc. announces the latest phase IIb clinical trial results of subcutaneous PD-L1 antibody ASC22 (envafolimab) in patients with chronic hepatitis B (CHB) at an oral parallel session of the International Liver Congress 2022 (ILC 2022) held by the European Association for the Study of the Liver (EASL). The interim report is based on a randomized, single-blind, multi-center phase IIb clinical trial to assess the efficacy and safety of ASC22 in treatment of CHB patients (ClinicalTrials.gov Identifier: NCT04465890). In 1.0 mg/kg ASC22 cohort, 75 CHB patients were randomized to be treated with 1.0 mg/kg ASC22 (n=60) or placebo (PBO, n=15) once every 2 weeks (Q2W) plus nucleos(t)ide analogs (NAs) for 24-week and then followed for another 24 weeks. The key findings from the phase IIb clinical study on ASC22: 42.9% patients with baseline HBsAg =100 IU/mL (n=7) obtained sustained HBsAg loss; ALT flares were observed on 21% patients in ASC22 group (n=48) while none in PBO group; Patients with ALT flares had more HBsAg reduction. Among the three patients with sustained HBsAg loss, two experienced ALT flares; One patient obtained sustained HBsAg loss starting at Week Four after two doses of ASC22 and experienced a transient seroconversion of anti-HBs at Week 28. This patient stopped NAs treatment three days after 24-week treatment of ASC22, and HBsAg still remained negative until end of the study; Most adverse events (AEs) (97.5%) were Grade 1-2, and no study drug-related serious adverse event (SAE) was reported.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!